This document discusses how coronary artery calcium scoring using computed tomography (CT) and levels of the inflammatory marker C-reactive protein (CRP) can be used together to predict cardiovascular risk. It finds that higher calcium scores and CRP levels each indicate greater risk of future heart attacks and cardiac deaths. The combination of an intermediate calcium score and elevated CRP may identify patients who would benefit from more aggressive prevention treatment and closer follow-up. The document recommends using calcium scoring and CRP testing together in asymptomatic individuals to help refine clinical decision making and prevention strategies.
Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...CTSI at UCSF
Presented by Philip Greenland, MD, at UCSF's symposium "The Role of Risk Stratification and Biomarkers in Prevention of Cardiovascular Disease" in Jan 2012.
Coronary Calcium and other CVD Risk Biomarkers: From Epidemiology to Comparat...CTSI at UCSF
Presented by Philip Greenland, MD, at UCSF's symposium "The Role of Risk Stratification and Biomarkers in Prevention of Cardiovascular Disease" in Jan 2012.
Join Dr. Emily Chan presentation on the latest research and treatments for colorectal cancer patients presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Join Dr. Emily Chan presentation on the latest research and treatments for colorectal cancer patients presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
We went over the workspace for the Star Wars & Minecraft Puzzle games on Code.org. I also explain what coding is & show a funny kid video (Kids React to Old Computers) Then the kids went through the puzzles.
Slideshow used for the Hour of Code Kickoff Assembly at STEAM Middle School. Includes and interactive unplugged coding activity, videos, and house challenge.
Hour Of Code : A Sample Lesson With Links To ActivitesJill Hubbard
Hour Of Code
Have your class, school, district, organization participate in the Hour Of Code 2015!
This presentation describes what Hour Of Code is,when it is, why you should participate, and provides a sample lesson and links to hour of code activities.
Links to youtube videos:
Slide 2: https://www.youtube.com/watch?v=2DxWIxec6yo
Slide 6: https://www.youtube.com/watch?v=FC5FbmsH4fw
Hour of Code 2015
What, When, Why, How?
Sample Lesson Plan Across Grade Bands
Quando a competição de empresas não maduras reduz seu custo do capital?Felipe Pontes
Contribuições do artigo:
Evidências de que os ECVs podem impactar o COC;
A competição por informações de empresas não maduras (mais opacas) é mais importante para redução do COC das empresas que já têm um custo do capital alto (ambiente informacional ruim); e
É importante que as empresas estimulem a competição por suas informações, principalmente nas fases mais opacas informacionalmente do seu ciclo de vida.
Divulgação do PPGCC e Eventos da UFPB 2015Felipe Pontes
Essa apresentação foi feita no III Talking Management, no dia 28/09/2015 no Unibê Business School.
Nesta apresentação são divulgados os eventos da UFPB, assim como o nosso PPGCC.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
2. 1.25
1.6
1.6
1.8
2.15
2.35
2.5
5
0 2 4 6 8 10
Lp(a)
Homocysteine
TC
Fibr
t-PA Ag
TC/HDL
hs-CRP
hs-CRP + TC/HDL
RR in men from the
Physicians Health Study
Risk of MI in Apparently Healthy PeopleRisk of MI in Apparently Healthy People
Values in the Highest Quartile Compared to Lowest Quartile
3. hs C-Reactive Proteinhs C-Reactive Protein
AtAt PRESENTPRESENT the following has been established:the following has been established:
o Values in the upper tercile (or quartile) confer a 2+ risk MI/SCDValues in the upper tercile (or quartile) confer a 2+ risk MI/SCD
o Marker likely for “endothelial dysfunction”Marker likely for “endothelial dysfunction”
o May have a role in “promoting atherogenesis”May have a role in “promoting atherogenesis”
o Values altered by:Values altered by: Increased By Decreased ByIncreased By Decreased By
Elevated BP ETOH consumptionElevated BP ETOH consumption
BMI Aerobic exerciseBMI Aerobic exercise
Metabolic syndrome Weight lossMetabolic syndrome Weight loss
Hormone use Medications:Hormone use Medications:
Chronic infections statins, fibrates,Chronic infections statins, fibrates,
Chronic inflammation niacinChronic inflammation niacin
4. hs C-Reactive Proteinhs C-Reactive Protein
o May or may not be related to the severity or extent of diseaseMay or may not be related to the severity or extent of disease
o This could be due to differences in chronicity or “pattern”This could be due to differences in chronicity or “pattern”
o CRP may be more related to “acceleration of atherosclerosis”CRP may be more related to “acceleration of atherosclerosis”
rather than its extentrather than its extent
6. CT Coronary Artery CalciumCT Coronary Artery Calcium
No CalcificationNo Calcification Severe CalcificationSevere Calcification
Left Main
LAD
LCX
AoAo
LALA
PAPA
7. Coronary Calcium Area by EBT andCoronary Calcium Area by EBT and
Coronary Artery Plaque AreaCoronary Artery Plaque Area
0
2
4
6
8
10
12
14
16
0 2 4 6 8
Square Root Sum of Calcium Areas
SquareRootSumof
PlaqueAreas
Rumberger, Circ 1995:92:2157-62
n = 38n = 38
r = 0.90r = 0.90
p < .001p < .001
8. No. of coronary segments/pt. with plaques (IVUS)No. of coronary segments/pt. with plaques (IVUS)
0 1 2 3 4 5 6 7
No. of calcifiedNo. of calcified
coronarycoronary
segments/pt.segments/pt.
(EBCT)(EBCT)
0
1
2
3
4
5
6
7
Y = -0.67 + (0.90 * X)
r = 0.86
p < 0.0001 N = 40 patients
total of 222 coronary
segments examined
# of segments with EBT calcium vs. # of segments with any plaque# of segments with EBT calcium vs. # of segments with any plaque
Schmermund et alSchmermund et al
AJC 1998; 81:AJC 1998; 81:
141-146141-146
9. EBT and Coronary Artery CalciumEBT and Coronary Artery Calcium
Define the extent of ASO disease?Define the extent of ASO disease?
YESYES
The amount of calciumThe amount of calcium correlates DIRECTLYcorrelates DIRECTLY toto
the amount of measurable coronary disease by:the amount of measurable coronary disease by:
1) direct histopathologic comparison1) direct histopathologic comparison
2) with intravascular ultrasound2) with intravascular ultrasound
10. 3
4.4
8.8
0
2
4
6
8
10
Score 0 Score 1-15 Score 16-
80
Score 81-
270
Score
>271
Relative Risk for Future CV Events using EBCT:Relative Risk for Future CV Events using EBCT:
926 initially asymptomatic patients926 initially asymptomatic patients
1st Quartile1st Quartile 2nd Quartile2nd Quartile 3rd Quartile3rd Quartile 4th Quartile4th Quartile
* AdjustedAdjusted for age, gender, hypertension, past/current smoking, and diabetesfor age, gender, hypertension, past/current smoking, and diabetes
Wong and Detrano, et al [Am J Cardiol 2000;86:495-498Wong and Detrano, et al [Am J Cardiol 2000;86:495-498
RelativeRisk(RR)RelativeRisk(RR)
11. Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients:
EBTEBT
Raggi et al AHJ 2001;141:193-199Raggi et al AHJ 2001;141:193-199
0.36 0.51 0.71
0.99
1.38
1.92
2.64
3.62
4.9
6.54
0
1
2
3
4
5
6
7
0 10 20 30 40 50 60 70 80 90
Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score
676 initially asymptomatic patients676 initially asymptomatic patients
3232++7 months f/u7 months f/u
AnnualAnnual AbsoluteAbsolute RiskRisk
12. EBT CVSEBT CVS (volume score)(volume score) Progression and MIProgression and MI
Raggi, Shaw, Callister, Budoff; JACC 2003Raggi, Shaw, Callister, Budoff; JACC 2003 (retrospective analysis)(retrospective analysis)
0
10
20
30
40
50
60
No MI MI
MeanChangeinCVS/yearMeanChangeinCVS/year
26+1.5%
47.5+7.5% *
n = 833, 2.1+1.4 yr f/u,
45 documented MI (2.2%/yr)
Stepwise Cox Model
Independent Predictors of MI
Elevated cholesterol
Diabetes
Initial EBT-CVS
% Change in EBT-CVS
Initially asymptomatic patients with CVS > 30 and repeat EBT Scans
13. Coronary Artery CalcificationCoronary Artery Calcification
AtAt PRESENTPRESENT the following has been established:the following has been established:
o Coronary calcium IS AtherosclerosisCoronary calcium IS Atherosclerosis
o The magnitude of the calcium score relates to the severity of ASO diseaseThe magnitude of the calcium score relates to the severity of ASO disease
o The calcium score as well as the percentile rank provide informationThe calcium score as well as the percentile rank provide information
in which to view risk factors, rather than the other way aroundin which to view risk factors, rather than the other way around
o The data on examining progression of CAD with CT are consistent withThe data on examining progression of CAD with CT are consistent with
the potential for the calcium score/rank to be used as the “goal” of therapythe potential for the calcium score/rank to be used as the “goal” of therapy
14. RR of non-fatal MI/Cardiac Death:
EBT Score and hs-CRP
6.3 4.3
1.74.9
1.8 1
0
2
4
6
8
High CAC Med. CAC Low CAC
Lowest quartile
hs-CRP
Highest quartile
hs-CRP
Park et al.
Circ. 2002;106-2073-2077
6.3
RelativeRiskRelativeRisk
6.4 yr. f/u, n = 967
initially asymptomatic,
non-diabetic individuals
15. Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients:
EBTEBT
0
1
2
3
4
5
6
7
0 10 20 30 40 50 60 70 80 90
Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score
LowLow
RiskRisk
IntermediateIntermediate
RiskRisk
HighHigh
RiskRisk
16. Prediction of MI/SCD in Asymptomatic Patients:Prediction of MI/SCD in Asymptomatic Patients:
EBTEBT
0
1
2
3
4
5
6
7
0 10 20 30 40 50 60 70 80 90
Percentile Rank for Baseline EBCT Calcium ScorePercentile Rank for Baseline EBCT Calcium Score
LowLow
RiskRisk
IntermediateIntermediate
RiskRisk
HighHigh
RiskRisk
CRP
CRP
17. Clinical Questions in PreventionClinical Questions in Prevention
In the asymptomatic individual
How aggressive should I be?
Primary versus secondary prev. goals
How closely should I follow up?
Routine versus close & repeat testing
18. hs-CRP CAC Range Level of Aggression, f/u
< 1 mg/L
> 1-3 mg/L
> 3 mg/L
hs-CRP & CAC Scoringhs-CRP & CAC Scoring
Value Range Percentile Range Aggression Clinical f/u
Low
Low
Low
Mod.
Mod.
Mod.
High
High
High
<25th
Low
>25th
-<75th
Intermed.
>75th
High
<25th
Low
>25th
-<75th
Intermed.
>75th
High
<25th
Low
>25th
-<75th
Intermed.
>75th
High
Primary Routine
Primary Routine
Secondary Close
Primary Routine
Primary Close
Secondary Close
Primary Close
Secondary Close
Secondary Close
19. hs-CRP & CAC Scoringhs-CRP & CAC Scoring
In “intermediate” risk asymptomatic individualsIn “intermediate” risk asymptomatic individuals
CAC Scanning with CTCAC Scanning with CT
&&
hs-CRP testinghs-CRP testing
areare ComplementaryComplementary to each otherto each other
and the combination of bothand the combination of both
can be used to refinecan be used to refine
Clinical-Decision making in such patientsClinical-Decision making in such patients